Quantification of Follicle Stimulating Hormone (follitropin alfa): Is In Vivo Bioassay Still Relevant in the Recombinant Age?

R. Driebergen, G. Baer

Disclosures

Curr Med Res Opin. 2003;19(1) 

In This Article

Conclusions

Extensive analyses have shown that Serono's r-hFSH (Gonal-F) has extremely high physico-chemical and biological consistency, which is reflected in its status as the first FbM r-hFSH. As a result, Gonal-F can now be characterised by non-bioassay methodology; Serono uses an optimised SE-HPLC technique for quantification of r-hFSH protein in both the drug substance and final product. Not only is this method far more precise than the Steelman-Pohley in vivo bioassay, representing a significant improvement in product quality and batch-to-batch consistency, but it also reduces the necessity to sacrifice tens of thousands of laboratory animals. In prescribing Gonal-F FbM, clinicians can be assured that they are using a product manufactured to the highest standards of quality and consistency that delivers a guaranteed dose. In conclusion, therefore, in view of the well-known drawbacks of in vivo bioassay, methods such as SE-HPLC are likely to gain increasing popularity for quality testing and regulatory purposes, provided that the manufacturing process is well controlled, fully validated and results in a protein product of highly consistent physico-chemical properties.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....